Immutep Says Root Cause Analysis Identified N-Glycan Structural Differences Between 200 L And 2,000 L Efti Batches Used In Discontinued TACTI-004; Contracts New 200 L Run, Targets Next Trial Start In 2H CY2027

Immutep Receives A$652,248 Grant From Monash University Under Australian Research Council's Linkage Projects Scheme For Research Collaboration

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce

Immutep Says It Received Nasdaq Notice Confirming It Regained Compliance With Minimum Bid Price Rule

Immutep Receives A$856,669 Cash Rebate From Australian Federal Government’s R&D Tax Incentive Program

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.